Compare
SELLAS Life Sciences Group, Inc. vs Adagene Inc. vs Cumberland Pharmaceuticals Inc vs Northwest Biotherapeutics Inc
| Latest fiscal year | SELLAS Life Sciences Group, Inc. SLS | Adagene Inc. ADAG | Cumberland Pharmaceuticals Inc CPIX | Northwest Biotherapeutics Inc NWBO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $7.67M | $44.52M | $1.38M |
| Revenue growth (YoY) | n/a | n/m | +17.6% | -0.3% |
| Gross margin | n/a | n/a | 85.0% (computed) | n/a |
| Operating margin | n/a | -279.5% | -6.3% | n/m |
| Net margin | n/a | -229.6% | -6.4% | n/m |
| Net income | -$26.86M | -$17.61M | -$2.84M | -$60.16M |
| EPS (Diluted) | -$0.25 | -$0.30 | -$0.19 | -$0.04 |
| Operating cash flow | -$28.39M | -$15.66M | $4.93M | -$44.76M |
| Free cash flow | n/a | -$15.67M | $4.83M | -$46.27M |
| Cash & equivalents | $71.79M | $74.52M | $11.44M | $3.04M |
| Total assets | $78.34M | $78.26M | $76.82M | $81.29M |
| Total liabilities | $7.47M | $26.36M | $52.28M | $128.86M |
| Shareholders' equity | $70.87M | $35.35M | $24.88M | -$60.28M |
| Return on year-end equity | -37.9% | -49.8% | -11.4% | n/a |
| Shares outstanding | 153.10M | 59.23M | 14.96M | 1.56B |
Revenue, most recent five fiscal years
| Fiscal year | SELLAS Life Sciences Group, Inc. | Adagene Inc. | Cumberland Pharmaceuticals Inc | Northwest Biotherapeutics Inc |
|---|---|---|---|---|
| Latest | $0 Ended 2023-12-31 | $7.67M Ended 2025-12-31 | $44.52M Ended 2025-12-31 | $1.38M Ended 2025-12-31 |
| 1 year earlier | $1.00M Ended 2022-12-31 | $103.2K Ended 2024-12-31 | $37.87M Ended 2024-12-31 | $1.38M Ended 2024-12-31 |
| 2 years earlier | $7.60M Ended 2021-12-31 | $18.11M Ended 2023-12-31 | $39.55M Ended 2023-12-31 | $1.93M Ended 2023-12-31 |
| 3 years earlier | $1.90M Ended 2020-12-31 | $9.29M Ended 2022-12-31 | $42.01M Ended 2022-12-31 | $1.68M Ended 2022-12-31 |
| 4 years earlier | $0 Ended 2019-12-31 | $10.18M Ended 2021-12-31 | $35.05M Ended 2021-12-31 | $1.00M Ended 2021-12-31 |